vs
Orthofix Medical Inc.（OFIX）与RPC INC（RES）财务数据对比。点击上方公司名可切换其他公司
RPC INC的季度营收约是Orthofix Medical Inc.的1.9倍（$425.8M vs $219.9M），RPC INC净利率更高（-0.7% vs -1.0%，领先0.3%），RPC INC同比增速更快（27.0% vs 2.0%），RPC INC自由现金流更多（$31.2M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 6.2%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
RPC集团是总部位于英国的企业，曾是欧洲规模最大的塑料包装供应商之一，总部坐落于北安普敦郡的拉什登。该公司此前在伦敦证券交易所上市，2019年被贝瑞全球集团收购，贝瑞全球集团又于2025年被安海斯包装收购。
OFIX vs RES — 直观对比
营收规模更大
RES
是对方的1.9倍
$219.9M
营收增速更快
RES
高出25.0%
2.0%
净利率更高
RES
高出0.3%
-1.0%
自由现金流更多
RES
多$14.4M
$16.8M
两年增速更快
OFIX
近两年复合增速
6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $425.8M |
| 净利润 | $-2.2M | $-3.1M |
| 毛利率 | 71.1% | 21.0% |
| 营业利润率 | 0.2% | -0.9% |
| 净利率 | -1.0% | -0.7% |
| 营收同比 | 2.0% | 27.0% |
| 净利润同比 | 92.4% | -124.0% |
| 每股收益（稀释后） | $-0.05 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXRES
| Q4 25 | $219.9M | $425.8M | ||
| Q3 25 | $205.6M | $447.1M | ||
| Q2 25 | $203.1M | $420.8M | ||
| Q1 25 | $193.6M | $332.9M | ||
| Q4 24 | $215.7M | $335.4M | ||
| Q3 24 | $196.6M | $337.7M | ||
| Q2 24 | $198.6M | $364.2M | ||
| Q1 24 | $188.6M | $377.8M |
净利润OFIXRES
| Q4 25 | $-2.2M | $-3.1M | ||
| Q3 25 | $-22.8M | $13.0M | ||
| Q2 25 | $-14.1M | $10.1M | ||
| Q1 25 | $-53.1M | $12.0M | ||
| Q4 24 | $-29.1M | $12.8M | ||
| Q3 24 | $-27.4M | $18.8M | ||
| Q2 24 | $-33.4M | $32.4M | ||
| Q1 24 | $-36.0M | $27.5M |
毛利率OFIXRES
| Q4 25 | 71.1% | 21.0% | ||
| Q3 25 | 72.2% | 25.1% | ||
| Q2 25 | 68.7% | 24.5% | ||
| Q1 25 | 62.8% | 26.7% | ||
| Q4 24 | 69.0% | 25.4% | ||
| Q3 24 | 68.7% | 26.7% | ||
| Q2 24 | 67.8% | 28.0% | ||
| Q1 24 | 67.5% | 26.8% |
营业利润率OFIXRES
| Q4 25 | 0.2% | -0.9% | ||
| Q3 25 | -8.3% | 4.7% | ||
| Q2 25 | -7.9% | 3.7% | ||
| Q1 25 | -25.2% | 3.7% | ||
| Q4 24 | -5.3% | 3.1% | ||
| Q3 24 | -9.6% | 5.7% | ||
| Q2 24 | -12.5% | 9.7% | ||
| Q1 24 | -15.6% | 8.6% |
净利率OFIXRES
| Q4 25 | -1.0% | -0.7% | ||
| Q3 25 | -11.1% | 2.9% | ||
| Q2 25 | -6.9% | 2.4% | ||
| Q1 25 | -27.4% | 3.6% | ||
| Q4 24 | -13.5% | 3.8% | ||
| Q3 24 | -13.9% | 5.6% | ||
| Q2 24 | -16.8% | 8.9% | ||
| Q1 24 | -19.1% | 7.3% |
每股收益（稀释后）OFIXRES
| Q4 25 | $-0.05 | $-0.02 | ||
| Q3 25 | $-0.57 | $0.06 | ||
| Q2 25 | $-0.36 | $0.05 | ||
| Q1 25 | $-1.35 | $0.06 | ||
| Q4 24 | $-0.76 | $0.06 | ||
| Q3 24 | $-0.71 | $0.09 | ||
| Q2 24 | $-0.88 | $0.15 | ||
| Q1 24 | $-0.95 | $0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $210.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $1.1B |
| 总资产 | $850.6M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXRES
| Q4 25 | $82.0M | $210.0M | ||
| Q3 25 | $62.9M | $163.5M | ||
| Q2 25 | $65.6M | $162.1M | ||
| Q1 25 | $58.0M | $326.7M | ||
| Q4 24 | $83.2M | $326.0M | ||
| Q3 24 | $30.1M | $276.9M | ||
| Q2 24 | $26.4M | $261.5M | ||
| Q1 24 | $27.0M | $212.2M |
总债务OFIXRES
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXRES
| Q4 25 | $450.0M | $1.1B | ||
| Q3 25 | $442.5M | $1.1B | ||
| Q2 25 | $458.3M | $1.1B | ||
| Q1 25 | $458.3M | $1.1B | ||
| Q4 24 | $503.1M | $1.1B | ||
| Q3 24 | $525.9M | $1.1B | ||
| Q2 24 | $546.0M | $1.1B | ||
| Q1 24 | $570.3M | $1.0B |
总资产OFIXRES
| Q4 25 | $850.6M | $1.5B | ||
| Q3 25 | $832.6M | $1.5B | ||
| Q2 25 | $837.2M | $1.5B | ||
| Q1 25 | $823.1M | $1.3B | ||
| Q4 24 | $893.3M | $1.4B | ||
| Q3 24 | $867.9M | $1.3B | ||
| Q2 24 | $882.0M | $1.3B | ||
| Q1 24 | $906.0M | $1.3B |
负债/权益比OFIXRES
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $61.9M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $31.2M |
| 自由现金流率自由现金流/营收 | 7.6% | 7.3% |
| 资本支出强度资本支出/营收 | 4.9% | 7.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $52.9M |
8季度趋势，按日历期对齐
经营现金流OFIXRES
| Q4 25 | $27.7M | $61.9M | ||
| Q3 25 | $12.4M | $46.5M | ||
| Q2 25 | $11.6M | $53.1M | ||
| Q1 25 | $-18.4M | $39.9M | ||
| Q4 24 | $23.7M | $94.2M | ||
| Q3 24 | $11.7M | $70.7M | ||
| Q2 24 | $9.0M | $127.9M | ||
| Q1 24 | $-18.6M | $56.6M |
自由现金流OFIXRES
| Q4 25 | $16.8M | $31.2M | ||
| Q3 25 | $2.5M | $4.1M | ||
| Q2 25 | $4.5M | $10.0M | ||
| Q1 25 | $-25.1M | $7.6M | ||
| Q4 24 | $15.2M | $53.7M | ||
| Q3 24 | $6.3M | $19.1M | ||
| Q2 24 | $-360.0K | $52.9M | ||
| Q1 24 | $-29.1M | $3.8M |
自由现金流率OFIXRES
| Q4 25 | 7.6% | 7.3% | ||
| Q3 25 | 1.2% | 0.9% | ||
| Q2 25 | 2.2% | 2.4% | ||
| Q1 25 | -13.0% | 2.3% | ||
| Q4 24 | 7.0% | 16.0% | ||
| Q3 24 | 3.2% | 5.6% | ||
| Q2 24 | -0.2% | 14.5% | ||
| Q1 24 | -15.4% | 1.0% |
资本支出强度OFIXRES
| Q4 25 | 4.9% | 7.2% | ||
| Q3 25 | 4.8% | 9.5% | ||
| Q2 25 | 3.5% | 10.2% | ||
| Q1 25 | 3.5% | 9.7% | ||
| Q4 24 | 4.0% | 12.1% | ||
| Q3 24 | 2.7% | 15.3% | ||
| Q2 24 | 4.7% | 20.6% | ||
| Q1 24 | 5.6% | 14.0% |
现金转化率OFIXRES
| Q4 25 | — | — | ||
| Q3 25 | — | 3.59× | ||
| Q2 25 | — | 5.23× | ||
| Q1 25 | — | 3.31× | ||
| Q4 24 | — | 7.38× | ||
| Q3 24 | — | 3.76× | ||
| Q2 24 | — | 3.95× | ||
| Q1 24 | — | 2.06× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
RES
| Technical Service | $405.2M | 95% |
| Other | $8.8M | 2% |
| Nitrogen | $6.6M | 2% |
